Baijun Fang

Statistics

Publications

Citations

150

H-Index

Active since

2017

Affiliations

Zhengzhou University(Current)

Henan Cancer Hospital

Peking University

Sun Yat-sen University

Peking University Third Hospital

Baijun Fang is an author at Zhengzhou University specializing in refractory multiple myeloma, multiple myeloma treatment, and multiple myeloma therapy.

ORCID

Publications per year

2017–2023

Publications

Decitabine enhances tumor recognition by T cells through upregulating the MAGE-A3 expression in esophageal carcinoma

Xiaojuan Shi, Xinfeng Chen, Baijun Fang et al. · Biomedicine & Pharmacotherapy · 2019 · 35 citations · Full text

Medicine, Immunology, Oncology +17

The phase I clinical study of CART targeting BCMA with humanized alpaca-derived single-domain antibody as antigen recognition domain.

Lu Han, Quanli Gao, Keshu Zhou et al. · Journal of Clinical Oncology · 2019 · 31 citations

Life Sciences, Hematology, Immunology +17

Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study

Lugui Qiu, Zhongjun Xia, Chengcheng Fu et al. · BMC Medicine · 2022 · 25 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial

Zhongjun Xia, Yun Leng, Baijun Fang et al. · BMC Cancer · 2023 · 15 citations · Full text

Medicine, Oncology, Pharmacology +14

Glutathione combined with mecobalamin in the treatment of chemotherapy-induced peripheral neuropathy in multiple myeloma: a retrospective clinical study

Hao Huang, Min Zhao, Xi-Yang Liu et al. · Annals of Palliative Medicine · 2021 · 12 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

1–5 of 8